Medtronic Clears LigaSure Instrument for Hugo RAS System in U.S.
Event summary
- FDA cleared LigaSure™ RAS Maryland instrument for use with Hugo™ RAS system in U.S.
- LigaSure technology has been used in over 45 million procedures globally
- Hugo RAS system currently cleared for urologic procedures in U.S., with expansion plans for general and gynecologic surgeries
- Instrument seals and cuts vessels up to 7 mm in diameter, minimizing thermal spread
- LigaSure RAS Maryland instrument previously introduced in Europe in 2025 following CE Mark
The big picture
Medtronic's FDA clearance for the LigaSure instrument on its Hugo RAS system aligns with the growing adoption of robotic-assisted surgery in the U.S. This move strengthens Medtronic's position against market leader Intuitive Surgical by offering surgeons familiar vessel-sealing technology in a robotic workflow. The clearance is part of Medtronic's broader strategy to expand the Hugo system's indications across various surgical procedures, potentially increasing its market share in the rapidly evolving surgical robotics sector.
What we're watching
- Market Expansion
- The pace at which Medtronic expands Hugo RAS system indications beyond urology in the U.S.
- Competitive Positioning
- How this clearance affects Medtronic's competitive stance against Intuitive Surgical in the robotic-assisted surgery market
- Adoption Rates
- Whether the integration of LigaSure technology will accelerate Hugo RAS system adoption in U.S. hospitals